Quince Therapeutics, Inc. (to be renamed IRulya Therapeutics Inc.) — Form 8-K
Event date: October 7, 2026; report filed October 9, 2026. This is a corporate and leadership update, not a periodic financial-results filing.
Business context and reporting period
The filing reports executive and board changes, a corporate name change, and related governance actions. The company’s common stock is expected to begin trading as IRulya Therapeutics Inc. under ticker IRLA on Nasdaq Capital Market at the opening of trading October 12, 2026. The CUSIP and stockholder rights are unchanged.
Financial and operating metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other company financial-performance results.
Disclosed executive compensation includes annual base salary and target bonus: CEO Brigette Roberts, $600,000 and 50%; CFO John Militello, $440,000 and 45%; and COO Keith Fandrick, $450,000 and 45%. Militello is also eligible, subject to Board approval, for an inducement award of 80,000 restricted stock units vesting over four years.
Material changes
- Effective October 8, 2026, Dirk Thye resigned as CEO, Chief Medical Officer, and director; Brendan Hannah resigned as COO, Chief Business Officer, and Chief Compliance Officer.
- Brigette Roberts was appointed CEO, John Militello CFO, and Keith Fandrick COO, effective October 8. Militello also succeeds Hannah as principal financial and accounting officer.
- June Bray, David Lamond, Christopher Senner, and Thye resigned from the Board effective October 8. The filing states the resignations were not due to disagreements with the company.
- Catherine M. Bonuccelli, Leone Patterson, James Valentine, and Drayton Wise joined the Board effective October 8. Patterson chairs the Audit and Compensation Committees; Valentine chairs the Nominating and Corporate Governance Committee.
- The Board approved the name change from Quince Therapeutics, Inc. to IRulya Therapeutics Inc., effective 4:01 p.m. Eastern Time on October 9. Stockholder approval was not required.
- The Outside Director Compensation Policy was terminated effective October 7. The principal executive office moved to New Haven, Connecticut, effective October 10.
Outlook, risks, and unusual items
The filing provides no financial guidance or company outlook. It describes severance arrangements, generally conditioned on execution of a release: Roberts may receive 12 months of salary, 12 months of COBRA premiums, and 12 months of accelerated time-based award vesting upon termination without Cause. Fandrick may receive six months of salary upon termination without Cause. Militello’s agreement provides nine months of salary and a COBRA-related payment for termination without Cause outside a change-in-control period; specified qualifying terminations during a change-in-control period may trigger 12 months of salary, target bonus, 12 months of COBRA coverage, and full vesting of time-based awards.
Important facts for investors to verify
- Confirm the effective name change and the expected October 12 ticker and Nasdaq market changes.
- Review the filed employment, severance, and inducement-award agreements for complete terms and conditions.
- Monitor subsequent filings for financial results, financing needs, business strategy, and any further leadership or governance changes; this 8-K does not report those financial details.